Drug Profile
AR 12
Alternative Names: AR-12; NSC D728209; OSU-03012Latest Information Update: 07 May 2018
Price :
$50
*
At a glance
- Originator Ohio State University Research Foundation
- Developer Arno Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Acetate-CoA ligase inhibitors; Angiogenesis inhibitors; Apoptosis stimulants; Autophagy stimulants; HSP70 heat shock protein inhibitors; HSP90 heat-shock protein inhibitors; Molecular chaperone GRP78 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
- Discontinued Bacterial infections; Cryptococcosis; Onychomycosis; Tularaemia; Viral infections
Most Recent Events
- 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Viral infections (Zika virus infections) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
- 22 Dec 2017 Arno Therapeutics terminates its license for AR 12 before December 2017
- 22 Dec 2017 Discontinued - Preclinical for Bacterial infections in USA (PO)